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Poor vascularization of tissue-engineered constructs is a common challenge in 
regenerative medicine and there is a need to find an optimal cell source that is 
proangiogenic and aids in the neovascularization process. 
 
Endothelial progenitor cells (EPCs) are cells that participate in new blood vessel 
formation and regeneration of blood vessel endothelium in ischemic and hypoxic 
conditions. Two major types of EPCs are Myeloid Angiogenic Cells (MACs) and 
Endothelial Colony Forming Cells (ECFCs). MACs promote formation of new blood 
vessels via a paracrine mode of action. 
 
Co-cultures of mesenchymal stem cells (MSCs) with peripheral blood derived 
mononuclear cells (MNCs) have been shown to possess angiogenic differentiation 
potential by inducing the differentiation of MACs. 
 
This project aimed to test the functionality of MACs in a co-culture model with human 
umbilical vein endothelial cells (HUVECs). MACs with surface markers CD14 and CD31 
were isolated from MSC-MNC co-cultures using magnetic-activated cell sorting and 
allowed to grow in a Transwell® setup with HUVECs. Optimisation of culture conditions 
with MSCs and HUVECs was also done to see if tube formation is affected by fibronectin 
coating and the type of culture media used. 
 
Results show that co-cultures of MACs and HUVECs give rise to looping and branching 
tubular structures, such as those seen in de novo vascularization and that tube formation 
is favoured when cells were cultured in Endothelial Growth Media and on fibronectin 
coated surfaces. 
 
These kind of in vitro assays will aid in assessing the proangiogenic capabilities of MACs. 
Further studies elucidating which paracrine vasoactive factors affect tube formation in 
angiogenesis will help in producing clinically applicable tissue-engineered constructs 
with better vascularization. 
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1.1 Angiogenesis and vasculogenesis 
 
The process of new blood vessel formation from an already existing vascular network is 
known as angiogenesis. On the other hand, vasculogenesis refers to the de novo formation 
of a primordial blood vessel network that is triggered by the differentiation of precursor 
angioblasts into endothelial cells. During early embryogenesis, both angiogenesis and 
vasculogenesis contribute to blood vessel formation. However, in a healthy adult, 
angiogenesis is limited to few physiological conditions, such as endometrium and 
placenta formation, wound healing, and hair follicle vascularization (Li et al., 2005).  
 
Angiogenesis is also seen in certain pathological conditions such as cancers, 
ophthalmological diseases, and chronic inflammatory diseases (Polverini, 1995). There 
is also evidence to suggest that post-natal vasculogenesis is possible due to the presence 
of endothelial cells and endothelial progenitor cells in the circulatory system (Ribatti et 
al., 2001). 
 
The dynamic process of angiogenesis involves several sequential steps (Figure 1). When 
tissue injury or neoplastic changes take place, the pre-existing vascular structure is 
disrupted. Angiogenesis is then initiated due to the cytokine secretion from monocytes, 
platelets, and fibroblasts (Bauer et al., 2005). Endothelial cells (ECs) which are a type of 
haematopoietic vascular stem cell are then recruited to the site of angiogenesis by growth 
factors such as vascular endothelial growth factor (VEGF), platelet derived growth factor 
(PDGF) and placental growth factor (PGF). Activated ECs then proliferate and produce 
outward sprouts in the direction of growth stimuli through the vascular basement 
membrane. Capillary sprout extension is then facilitated by adhesion molecules such as 
integrins that attach the cells to the surrounding extracellular matrix. Matrix 
metalloproteases (MMPs) are then released by the newly formed capillary tips thus 
dissolving the extracellular matrix (ECM) at the vascular front. Specialised ECs called 
‘tip cells’ then form filopodia like structures that help in guiding the movement of 
extending vessels. These structures use specific receptors to respond to both attractive 
(eg: VEGF) as well as repulsive (eg: Sema3A) cues in their surroundings. Vascular loops 
and branching tube-like structures are then formed by interactions between cell-cell and 
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cell-ECM. Vessels are then stabilised by smooth muscle cells and pericytes forming a 
covering around the newly formed capillaries, new basement membrane is formed and 
finally blood flow takes place (Li et al., 2005).  
 
During angiogenesis, pericytes are recruited by endothelial cells of newly formed vessels 
by secretion of PDGF-β. These cells with a prominent nucleus and several long processes 
are implicated in vasculogenesis by taking part in extracellular matrix modulation, 
paracrine signalling, and direct interaction with ECs. Pericytes are CD146+ and CD34- 
and they might represent a subpopulation of mesenchymal stem cells (MSCs) in the bone 
marrow and aid in development of early capillary sprouts (Loibl et al., 2014). Pericytes 
are technically not necessary during the initial stages of vasculature development but they 
induce vessel maturation as well as regulate microvessel integrity, structure, and function 

















Figure 1. Schematic diagram of angiogenesis process. Angiogenesis starts with the 
release of certain angiogenic cytokines. Growth factors facilitate recruitment of 
endothelial cells (ECs). Activated ECs then produce capillary sprouts, which then release 
matrix metalloproteases (MMPs) that dissolve the basement membrane. Specialised ECs 
then take part in vessel extension by responding to certain cues. Finally, neovessel 
formation takes place (Adapted from Bauer et al., 2005). 
 
STEP 1: Angiogenesis begins 
with the secretion of certain 
cytokines. 
STEP 2: ECs are recruited by 
growth factors to the site of 
angiogenesis.  
 
STEP 3: MMPs disrupt the ECM 
and specialized ECs respond to 
certain attractive cues leading to 
vessel extension. 
STEP 4: ECs proliferate, new 
blood vessel is formed and 
stabilized with the help of pericytes 
and smooth muscle cells. 
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Vasculogenesis was originally thought to take place only during foetal development but 
recent studies show that vasculogenesis also occurs in adults. In foetal vasculogenesis, 
endothelial progenitor cells (EPCs) known as angioblasts differentiate into ECs, thus 
forming a primitive vascular network. Postnatal vasculogenesis, on the other hand, is 
initiated by the differentiation of multipotent adult progenitor cells (MAPCs) into early 




















Figure 2. Diagrammatic illustration of steps involved in postnatal vasculogenesis 
Adult vasculogenesis starts with the differentiation of multipotent adult progenitor cells 
(MAPCs) into early EPCs. Growth factors such as VEGF and placental growth factor 
(PGF) then induce MMP secretion. This leads to conversion of membrane bound Kit 
ligand (mKitL) to soluble Kit ligand (sKitL), which in turn leads to mobilisation of early 
EPCs. These early EPCs in circulation then differentiate into late EPCs with specific EC 
markers. Late EPCs then further differentiate and give rise to mature ECs (Adapted from 





Growth factors such as VEGF and 
PGF induce secretion of MMPs 
which in turn leads to 
mobilization of early EPCs 
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Post-natal vasculogenesis is either triggered by local ischemic conditions or is injury 
driven. It is believed to take place when MAPCs present in the peripheral blood or bone 
marrow differentiate into early EPCs. These early EPCs express specific haematopoietic 
cell surface markers such as CD34, CD133 and VEGFR2. EPCs are then mobilised from 
the bone marrow into circulation by means of cytokine mediated pathways such as VEGF 
and stromal cell derived factor 1 (SDF-1). Increased levels of these growth factors act as 
activators and attach to their specific cell receptors and subsequently lead to increased 
secretion of MMPs. MMPs then facilitate the conversion of membrane bound Kit ligand 
(mKitL) to soluble Kit ligand (sKitL). This entire process is what sets off the mobilisation 
of early EPCs into circulation. Later these early EPCs differentiate into late EPCs with 
specific EC markers such as CD34, CD31, VEGFR2. These late circulating EPCs then 
arrive at the site of neovessel formation, act as sources for proangiogenic soluble factors 
or further differentiate and develop into mature ECs (Bauer et al., 2005). 
 
1.1.1 Angiogenesis and vasculogenesis as a therapeutic target 
 
Abnormal or improper angiogenesis and vasculogenesis can lead to several diseases. 
Therefore, angiogenesis itself can be used as a diagnostic or prognostic indicator in 
clinical applications. For instance, impaired angiogenesis has been linked to conditions 
such as coronary artery disease (CAD), cardiovascular diseases, and compromised wound 
healing, while increased angiogenesis is often seen in inflammatory diseases, such as 
atherosclerosis, malignant tumors, and diabetic retinopathy (Pandya et al., 2006). 
 
Angiogenesis and vasculogenesis are both indispensable processes for successful wound 
healing and tissue regeneration. Several diseases ranging from CAD to diabetic ulcers 
result in ischemia. Current treatment for these conditions ranges from invasive procedures 
such as stenting/surgery for CAD to palliative care for recurring diabetic wounds. Hence, 
there is a clear unmet clinical need for providing restoration of blood flow to ischemic 
areas through the generation of new blood vessels (Gianni-Barrera et al., 2020).  
 
Angiogenesis also plays a key role in bone tissue engineering. Bone tissue has certain 
inherent regenerative properties; however, sufficient endothelialisation of constructs is 
necessary for successful bone healing. Vascularization of engineered constructs before 
transplantation would greatly help in producing functional tissue engineered grafts. 
Insufficient vascularization of these constructs is an ever-present medical challenge. 
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Several researchers have tried to show that implanting endothelial cells and pericytes into 
these constructs may provide a way to induce de novo vascular network formation (Jain 
et al., 2005).  
 
Currently various methods by which vascularization of tissue engineered constructs can 
be improved are being studied by researchers. These methods include but are not limited 
to, modification of chemical composition of scaffolds, incorporation of proangiogenic 
cytokines at the site of implantation and seeding of constructs with vasculogenic cells 
(Laschke and Menger, 2012). This technique of cell seeding in particular can help 
augment vascularization by a few different mechanisms. Seeded cells can either stimulate 
angiogenesis by releasing certain proangiogenic growth factors or in the case of stem 
cells, they can differentiate into vascular cells capable of de novo vascularization. For 
instance, Schumann et al., have demonstrated that when both osteoblast-like cells and 
bone marrow derived mesenchymal stem cells were seeded onto poly(L-lactide-co-
glycoid) (PLGA) scaffolds, accelerated vascularization took place in the scaffolds due to 
increased expression of VEGF (Schumann et al., 2009). Liu et al., have shown that when 
mouse models were implanted with co-cultured umbilical cord blood-derived EPC/MSC 
scaffold grafts, increased ectopic bone formation was observed in vivo (Liu et al., 2013). 
Despite all these findings, inadequate vascularization remains a challenge in the field of 
tissue engineering and regenerative medicine and finding solutions for this issue can help 
produce more clinically translatable constructs. 
 
 
1.2 Mesenchymal stem cells  
 
Mesenchymal stem cells (MSCs) are multipotent cells capable of differentiation into 
osteocytes, adipocytes, and chondrocytes both in vitro and in vivo (Oswald et al., 2004). 
These cells have been isolated from various tissue sources, such as adipose tissue, bone 
marrow, dental tissue pulp and umbilical cord blood (Ibraheim et al., 2017).  
The golden standard source for MSCs is the bone marrow. Bone marrow derived MSCs 
are key players in blood vessel formation, stabilisation, and regulation (Watt et al., 2013).  
 
Depending on the tissue they are isolated from, MSCs show variations in their 
differentiation capacity, immunophenotype and immunomodulatory activity. These 
differences confer different MSCs with specific characteristics and features (Guo et al., 
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2020). There are certain prerequisites that MSCs should meet and these criteria are 
defined by the International Society for Cellular Therapy (ISCT). The first requirement 
is that MSCs show plastic adherence when cultured in vitro. Second, MSCs should 
express certain specific cell surface markers such as CD73, CD90, and CD105 and lack 
the expression of CD45, CD34, CD14 or CD11b, CD79α or CD19 and HLA-DR. Finally, 
MSCs should differentiate into three separate cell lineages (osteoblasts, chondrocytes, 
adipocytes) when cultured under specific conditions and supplemented appropriately 
(Hmadcha et al., 2020).  
 
MSCs are a lucrative cell source within the field of tissue engineering and regenerative 
medicine. Researchers have tried to harness the mesodermal differentiation potential of 
MSCs for various indications such as autoimmune diseases, musculo-skeletal defects, and 
cardiovascular diseases (Gomez-Salazar et al., 2020). The therapeutic potential of MSCs 
is mainly facilitated by their innate ability to migrate towards the sites of injury. 
Transplanted MSCs produce certain paracrine soluble biomolecules such as cytokines 
and growth factors that promote angiogenesis, cell survival and tissue regeneration 
(Hmadcha et al., 2020). Several studies have shown that both myeloid cells and MSCs 
enhance the vasculogenic properties of endothelial colony forming cells (ECFCs) in in 
vivo as well as in vitro models, showing the formation of de novo vasculature network 
(Watt et al.,2013).   
 
The exact mechanisms by which MSCs contribute to tissue repair during injury are not 
known. One hypothesis is that these cells play a key role in the recruitment of 
macrophages and fibroblasts to the site of injury by secreting certain paracrine growth 
factors such as VEGF, keratinocyte growth factor, insulin-like growth factor and 
angiopoietin-1. This in turn promotes angiogenesis and collagen production thus reducing 
the risk of scar formation (Ibraheim et al., 2017).  MSCs further enhance differentiation 
of ECs via VEGF secretion. VEGF is an important growth factor that is explicitly 









1.3 Peripheral blood-derived mononuclear cells 
 
Peripheral blood-derived mononuclear cells (PB-MNCs) are a heterogeneous population 
of blood cells, such as lymphocytes, monocytes, natural killer cells, and dendritic cells. 
They are identified by their round nucleus and as their name indicates, can be isolated 
from peripheral blood. They are obtained by minimally invasive procedures and are hence 
an easy and accessible source. MNCs have been used by researchers for various purposes 
ranging from immunomodulatory studies to cytokine secretion studies (Kleiveland C.R., 
2015). Their differentiation potential into multiple cell types, such as endothelial cells, 
cardiomyocytes, osteoblasts etc. makes them an attractive cell source in the field of 
regenerative medicine (Zhang and Huang, 2012).   
 
1.3.1 Endothelial progenitor cells  
 
In 1997, Asahara et al. provided a new insight that peripheral blood contains a cell 
population that is capable of differentiating into endothelial progenitor cells and since 
then EPCs derived from peripheral blood have been shown to be of various subtypes. 
These putative EPCs were isolated for the first time by means of magnetic bead separation 
based on surface antigens expressions. 
EPCs are generally isolated either from ex vivo/in vitro culture of PB-MNCs or by direct 
flushing of bone marrow and then expanding the cells in endothelial cell culture 
conditions (George et al., 2011). The term EPC is not an all-encapsulating term and 
generally refers to any cell that can differentiate into an endothelial cell line (George et 
al., 2011). Studies have shown that EPCs are capable of promoting revascularisation and 
this makes them ideal candidates for cell-based therapy strategies for ischemic diseases 
(Medina et al., 2011).  
 
In order to harness the full potential of EPCs for cellular therapy, appropriate validation 
of these cells and their secretome should be studied (Edwards et al., 2018). There is a lot 
of variation in the phenotypic markers used to identify EPCs. Based on the methodology, 
differences in expression of cell surface markers have been noted. EPCs that were 
quantified using flow cytometry techniques were shown to express CD34 and VEGFR2 
(Medina et al., 2017). Since CD34 and VEGFR2 are also expressed by circulating 
endothelial cells isolated from vasculature, some research groups have proposed that 
these cells also express CD133 as an additional progenitor marker (Medina et al., 2017). 
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However, this remains a controversial opinion. There is contrasting evidence that 
CD34+CD133+ cells give rise to endothelial cells but also CD34+CD133+VEGFR2+ cells 
have been shown to remain haemopoietic instead of giving rise to endothelium (Medina 
et al., 2017). 
 
Interestingly, when EPCs were isolated using cell culture-based technologies, two distinct 
type of EPC subset populations with vasoreparative properties were observed (Medina et 
al., 2017). These two major classes of cells based on their phenotypic lineage are cells of 
haematopoietic lineage and cells of endothelial lineage (Table 1). Myeloid Angiogenic 
Cells (MACs) belong to the first class, while Endothelial Colony Forming Cells (ECFCs) 
belong to the latter class. Other cells that fall under the group of haematopoietic lineage 
are circulating angiogenic cells, early EPCs, early outgrowth EPCs, haematopoietic 
EPCs, small EPCs, and myeloid EPCs. On the other hand, outgrowth endothelial cells, 
blood outgrowth endothelial cells, endothelial outgrowth cells, late EPCs, late outgrowth 
EPCs, non-haematopoietic EPCs and large EPCs are of endothelial lineage (Medina et 
al., 2017).  
 
  Table 1. Cell types classified based on their phenotypic lineage (Adapted from Medina 
et al., 2017). 
Haematopoietic Lineage Endothelial Lineage 
Myeloid Angiogenic Cells (MACs) Endothelial Colony Forming Cells (ECFCs)  
Circulating Angiogenic Cells (CACs) Outgrowth Endothelial Cells (OECs)  
Early EPCs Blood Outgrowth Endothelial Cells (BOECs) 
Early outgrowth EPCs  Late outgrowth EPCs 
Myeloid EPCs  Late EPCs 
 
Researchers have shown that EPCs that were first cultured in vitro and then transplanted 
into ex vivo models augmented the neovascularisation process even if these cells were not 
supplemented with any external proangiogenic factors (Asahara and Kawamoto, 2004). 
These types of findings help to propagate the idea that perhaps EPCs are capable of acting 
as a stable source of ECs and may be able to supplement pre-existing ECs in the vascular 
networks. In addition, genetic modification of these EPCs may be another avenue to look 
into for therapeutic purposes. Genetically altering EPCs to express and produce more 
angiogenic growth factors may even help address the limitations of EPC transplantation 
strategies (Asahara and Kawamoto,2004). 
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1.3.2 Myeloid angiogenic cells 
 
Early EPCs are also known as circulating angiogenic cells (CACs). However, sufficient 
proof is not available to show that these CACs would exist in vivo. It has been suggested 
that CACs can be generated in vitro when PB-MNCs are cultured in endothelial cell 
culture conditions. These cultured cells are then termed as myeloid angiogenic cells 
(MACs). It is thought that MACs augment angiogenesis/tubulogenesis through a 
paracrine mode of action by secreting certain paracrine vasoactive biomolecules, while 
ECFCs boost both in vitro and in vivo tube formation capacity due to their intrinsic 
vasoreparative and vasculogenic potential. ECFCs act as foundational cells capable of 
promoting new vascular tube formation as well as aid in repair of vascular structures 
(Medina et al., 2017). 
 
Medina et al., have also highlighted the distinction between MACs and ECFCs based on 
their cell surface markers. MACs are cells that are positive for CD45, CD14 and CD31 
surface markers. They do not express CD146 and CD34 markers. ECFCs are those cells 
that express CD31, CD105 and CD146 markers but are negative for CD45 and CD14.  
 
Sieveking et al. (2008) showed that early EPCs do not participate in de novo tubule 
formation however when these same early EPCs were co-cultured with endothelial cells 
and fibroblasts in a Transwell® setup, they were shown to stimulate the tubulogenesis 
process in a dose-dependent manner, suggesting that these cells have a paracrine effect. 
 
It should be noted that MACs are neither endothelial nor progenitors in nature, they are 
simply monocytic, myeloid cells that are of haematopoietic origin and capable of 
stimulating angiogenesis (Medina et al., 2017). 
 
 
1.4 Pericytes and endothelial cells   
 
The entire blood vascular network is lined by a single thin layer of endothelial cells and 
a few scattered pericytes. Pericytes are the cells present on the basement membrane of 
endothelial cell tubes. These cells interact through transmembrane and perform two major 
functions: provide structural support and integrity to vascular structures as well as 
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maintain constant microvasculature blood flow (Ribatti et al., 2011). There is also an 
interplay between pericytes and endothelial cells that takes place.  
 
Pericytes help in EC proliferation, migration, and stabilisation and in turn ECs aid in the 
activation of pericyte precursor population (Ribatti et al., 2011). These cells are key 
players during the process of angiogenesis and new capillary tubes are formed from 
existing endothelial cells by means of sprouting. This new sprout then hollows out to form 
tubular blood vessels. These capillaries then connect with other capillaries and 
anastomose thus facilitating blood circulation (Alberts et al., 2002).  
 
Human umbilical vein endothelial cells (HUVECs) are endothelial cells isolated from the 
umbilical vein and are a widely used model to study angiogenesis and tube formation 
(Kocherova et al., 2019). These cells are readily available commercially, easy to sustain 
in vitro and proliferate well. HUVECs can be used in in vitro assays to mimic the body’s 
vasculature network and to assess how soluble proangiogenic factors can affect the ability 
of these endothelial cells to form tubular structures. 
 
 
1.5 Cell-cell communication in angiogenesis and vasculogenesis 
 
Cell communication are of various types i.e., autocrine, endocrine, paracrine, and direct 
cell-cell contact (Herzog et al., 2014). Understanding the cellular crosstalk and molecular 
mechanisms behind angiogenesis will help to pinpoint which soluble factors and cells 
play a key role in vascularization process. Co-culture setups, in particular, are very useful 
for researchers as it helps us to study how cells communicate with each other based on 
soluble growth factors, cellular contact, and extracellular matrix components (Kirkpatrick 
et al., 2011). 
 
Co-culture models have also been used to find in vivo strategies that can help enhance 
endothelial tube formation or aid in neovascularisation process. These type of synergistic 
models are in particular very useful in the field of bone tissue engineering, where 
production of a fully functional and vascularised bone tissue construct is a major issue. 




In order to tackle the issue of insufficient vascularization of tissue engineered constructs, 
it is pertinent to understand how cells interact with one another and influence each other.  
 
Cells can also be co-cultured using a permeable Transwell® insert, which allows diffusion 
of soluble factors secreted by the cells. Here, the insert contains a specific cell population 
while the well contains another population, thus, preserving the cellular polarity. Such 
insert co-culture systems, which do not allow direct cell-cell contact can help researchers 
to study what type of paracrine signaling takes places between two or more cell 
populations (Renaud and Martinoli, 2016). 
 
Various cells have been cultured in a co-culture setup to study and understand the cellular 
mechanisms behind angiogenesis. Both MSCs and ECs have been heavily implicated as 
key players in neovascularisation. During angiogenesis, ECs give rise to primordial 
vascular plexus which are later remodelled into larger vessels (Lamalice et al., 2007). 
MSCs on the other hand are capable of differentiating into ECs which can take part in 
postnatal vascularization and secrete certain proangiogenic cytokines (Tao et al., 2016). 
MSCs have further also been shown to stabilize EC formed structures both in vivo and in 
vitro (Chen et al., 2018). Due to these reasons, MSCs and ECs are often investigated in 
co-culture models to understand how their interactions can help augment angiogenesis.  
 
For instance, Bidarra et al. (2011) have shown that MSCs co-cultured with HUVECs 
show significant improvement in proliferation rates and increased osteogenic 
differentiation potential. Oki et al. (2018) demonstrated that when MSCs were co-
cultured with HUVECs, lumen like structures were formed within 72 hours. They also 
showed that MSCs co-cultured with HUVECs produced tubular structures but HUVECs 
treated with VEGF alone did not produce any such vessels. Hyun Kim et al. (2013) 
showed that when CD31+ cells isolated from peripheral blood were co-cultured with 
HUVECs they showed higher potential of tube formation compared to CD31- or MNC 
alone culture groups. Xu et al. (2020) showed that when MSCs and ECs are co-cultured 
in a Transwell® setup, the paracrine signalling between these two cell types has a 
significant effect on the upregulation and osteogenic differentiation potential of MSCs.  
 
Several other studies have also shown that direct cellular contact with MSCs influence 
the formation of tubular structures by ECs. Similarly, when endothelial cells and pericytes 
are co-cultured, they very obviously interact with each other to promote and support 
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vessel assembly, growth control as well as normal microvasculature functions (Hirsch 
and D’amore, 1997; Peters, 2018).  Additionally, both HUVECs and MSCs are suggested 
to secrete specific growth factors that can support vascularization. Piard et al. (2019) have 
recently shown that the media in which HUVECs and MSCs were cultured tended to 
promote tube formation, which is a later stage of angiogenesis. 
 
 
1.6 Prior research using co-culture models of PB-MNCs and MSCs 
 
Our lab has recently shown that spindle shaped EC-like cells are found in co-cultures of 
PB-MNCs and MSCs and these cells were further identified as MACs, capable of 
producing and enhancing formation of tube-like structures, when co-cultured with 
HUVECs in both 2D and 3D culture setups (Uusitalo-Kylmälä et al., 2021). However, in 
this study, the exact proangiogenic factors that mediated the formation of tube-like 
structures were not identified. Previously, our lab has also shown that when MSCs and 
MNCs were co-cultured and cultures were supplemented with exogenous VEGF, 
osteoblastic differentiation and bone formation by MSCs was improved (Joensuu et al., 
2015).  
 
These studies provide an insight that MSC-MNC co-cultures do produce an endothelial 
cell like population that is capable of enhancing neovascularisation and that MACs do 
function in a paracrine manner to promote tube formation in vitro. Since these studies 
already assessed the functionality of MACs when grown in direct co-culture setups, there 
was a potential to study how MACs interact with HUVECs when they were cultured in a 
Transwell® setup. Hence, this master’s thesis project was carried out. 
 
 
1.7 Aim of the project    
 
This project can be divided into three parts. The first aim was to optimize the culture 
conditions for co-culturing MSCs and HUVECs. Then, we aimed to assess the cell-cell 
interactions and effect of MSCs on HUVECs to form tubular structures when cultured in 
a Transwell® setup. Finally, the major aim of this study was to test the functionality of 




Our lab has previously shown that when MACs and HUVECs are co-cultured in direct 
contact with each other, branching loops and tube-like structures similar to those seen 
during vasculogenesis are formed, suggesting that MACs are capable of supporting 
angiogenesis in vitro. This project therefore focused on studying if MACs secrete 
proangiogenic soluble factors, which will enhance tube formation, as well as to study if 
the MACs and HUVECs require cell-cell contact in order to secrete soluble factors.  
 
We hence hypothesized that MACs in a Transwell® setup will interact with HUVECs and 
induce them to form tube-like structures. The aim was to evaluate if tube formation is 
dependent on cell-cell contact or paracrine growth factors secreted by the cell populations, 
or both. MACs with surface markers CD14 and CD31 were isolated from MSC-MNC co-
cultures by magnetic-activated cell sorting and cultured in a Transwell® setup with 
HUVECs.  
 
Our research is mainly significant from a tissue-engineering perspective. Although tissue 
engineering is a promising avenue in the field of tissue healing and regeneration, we are 
still lacking the final clinical breakthrough. A major challenge is the inadequate 
vascularisation of the engineered constructs leading to poor survival of cells and tissue 
necrosis. Understanding the cellular crosstalk and molecular mechanisms behind 
neovascularization will help in construction of clinically stable tissue engineered 
constructs embedded with a strong vascular network. These would avoid the problems of 





2.1 Endothelial Growth Medium (EGM) and fibronectin promote network 
formation in co-cultures of MSCs and HUVECs 
 
In this part, we attempted to identify which culture conditions promote optimal tube-like 
structure formation when human umbilical vein endothelial cells (HUVECs) and 
mesenchymal stem cells (MSCs) are co-cultured. Our results show that when cells were 
cultured on plastic (i.e., not on fibronectin coated plates) or in Endothelial Growth 
Medium 2 (EGM 2), poor growth of cells, as well as minimal tube formation was 
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observed (Fig 3A, 3C and 3D). However, when HUVECs were co-cultured with MSCs 
in Endothelial Growth Medium (EGM) and in the presence of fibronectin coating, clear 
tube formation was seen (Fig 3B). The cells also survived well even after a week of 
culturing. By quantification, we noticed that the culture media used and fibronectin 
coating made a clear difference in the number of tubes formed (Fig 4A), the length of 
tubes (Fig 4B) as well as number of branchpoints of the network (Fig 4C). 
 
Figure 3. Images acquired from IncuCyte® S3 after a week of co-culturing MSCs and 
HUVECs in a 96-well culture plate with different culture setups. A: MSC and HUVEC 
cultured in EGM without fibronectin; B: MSC and HUVEC cultured in EGM with 
fibronectin; C: MSC and HUVEC cultured in EGM 2 without fibronectin and D: MSC 
and HUVEC cultured in EGM 2 with fibronectin. Red arrows indicate formation of tube-




























       
 
 
                                                                                 
Figure 4. Quantification of HUVEC networks using numerical data obtained from 
IncuCyte® Angiogenesis Analysis Software. HUVECs co-cultured with MSCs in EGM 
with fibronectin coating show the greatest number of networks (A) as well as the highest 









2.2 MSCs and HUVECs form tube-like structures when cultured in Transwell® 
setup  
Results from MSCs and HUVECs co-cultured in Transwell®  setup were quite similar to 
the previous optimisation experiment. Experimental groups which contained HUVECs in 
the well and MSCs in the Transwell® showed increased network formation per mm2 (Fig 
5A) and increased network length per mm/mm2 (Fig 5B). However, maximal network 
branch points were seen when HUVECs were cultured with both MSCs and HUVECs in 
the cell culture insert (Fig 5C).  
 
Further imaging with both normal light microscope (Fig 6) and multichannel fluorescence 
microscope (Fig 7) showed morphological changes and both short as well as elongated 
tubular structures. HUVECs cultured alone were used as control and presence of few 
elongated tube-like structures were observed in this group (Fig 6A and 7A). Microscopy 
imaging showed that when MSCs and HUVECs were co-cultured, elongated tubes were 
formed (Fig 6 B and 7B). When the experimental groups containing HUVECs in the well 
and MSCs in the cell culture insert (Fig 6C and 6D) as well as HUVECs with both MSCs 
and HUVECs in the cell culture insert (Fig 7C and 7D) were observed under the 
microscope, the presence of both short, as well as elongated and branched, tube-like 
structures were seen. Experiments were done twice and the microscopy images are from 
the first set of experiment, while the quantification results are from the second set, since 
there were technical issues with IncuCyte® imaging in the first experiment and the 








Figure 5. Quantification of HUVEC networks on day 7 from experiments where MSCs 
and HUVECs were co-cultured in Transwell®. When cells were co-cultured in the insert 
(blue bars), trends for better network formation per mm2, network length per mm/mm2 












Figure 6. Images acquired from light microscope showing formation of tube like structures 
by the co-cultured cells. A: HUVECs cultured alone; B: HUVECs and MSCs cultured 
together; C: HUVECs in the bottom of the well and MSCs alone in the Transwell® insert; D: 
HUVECs in the bottom of the well and HUVEC plus MSCs together in the Transwell® insert. 
















Figure 7. Images acquired from multichannel fluorescence microscope showing formation of 
elongated tubes (red arrows) by the co-cultured cells. A: HUVECs cultured alone; B: HUVECs 
and MSCs cultured together; C: HUVECs in the bottom of the well and MSCs alone in the 
Transwell insert; D: HUVECs in the bottom of the well and HUVEC plus MSCs together in the 


















2.3 MACs and HUVECs co-cultured in Transwell® setup give rise to looping and 
branching tube-like structures similar to those seen in de novo vascularization 
Upon co-culturing Myeloid Angiogenic Cells (MACs) isolated from MSC-MNC cultures 
with HUVECs for up to 14 days, we observed the formation of circular loops and 
branching tubular structures that resemble those seen in neovascularisation processes (Fig  
8 and 9). Experiments were carried out in triplicates to minimise variation. The 
microscopy images in (Fig 8 and 9) are from the third experiment.  Quantificiation of the 
tubular structures was done by using data from the IncuCyte® S3 Angiogenesis module. 
Variations in the time points that were used to quantify data are due to the fact that it was 
not always possible to consistently obtain good images with the IncuCyte®. 
Quantification results shown below (Fig 10 and 11) are from the first and third 
experiment. Images and quantification data from the second experiment are omitted here 
as there were issues with MACs isolation, which in turn led to very poor and inconsitent 
results. 
 
In the first attempt, the most number of networks per mm2 and network length per 
mm/mm2 were seen when HUVECs were co-cultured with MACs and HUVECs in a 
Transwell®  insert (Fig 10A and 10B). Results from the first set of experiments also show 
that network formation peaks around day 4 for all groups. This may be due to the secretion 
of certain paracrine growth factors by the cells. In the third experiment, maximal network 
formation per mm2 and network length per mm/mm2 were seen when HUVECs were co-
cultured with only MACs in the insert (Fig 11A and 11B). This indicates that MACs could 
secrete some soluble proangiogenic factors that promote tube formation. 
 
However, in both the first and third experiments, not much difference was seen between 
the groups when the number of network branch points were compared (Fig 10C and 11C).  
HUVECs cultured alone and HUVECs cultured with MACs without inserts were used as 
control. No tube-like structures were seen when the HUVECs only group was observed 
under the microscope, although, few circular loop like structures were seen when the 
HUVECs cultured with MACs without inserts were imaged using a light microscope (Fig 









Figure 8. Images acquired by multichannel fluorescence microscopy showing formation of 
elongated tubes (red arrows) by the co-cultured cells. A: HUVECs cultured alone; B: HUVECs 
and MACs cultured together; C: HUVECs in the bottom of the well and MACs alone in the 
Transwell® insert; D: HUVECs in the bottom of the well and HUVEC plus MACs together in 
the Transwell® insert. HUVECs cultured alone and HUVECs cultured with MACs without 
inserts were used as control. Magnification 10x.  










Figure 9. Images acquired by light microscopy showing formation of circular loops and 
branching elongated tubes (red arrows) by the co-cultured cells. A: HUVECs cultured alone; B: 
HUVECs and MACs cultured together; C: HUVECs in the bottom of the well and MACs alone 
in the Transwell® insert; D: HUVECs in the bottom of the well and HUVEC plus MACs together 
in the Transwell® insert. HUVECs cultured alone and HUVECs cultured with MACs without 











































Figure 10. Quantification results from the first experiment of MACs and HUVECs co-
cultured in Transwell. Network formation seems to peak at day 4 for all groups. However, 
increased networks per mm2 and increased network lengths per mm/mm2 at all time points 
are the highest, when HUVECs were co-cultured with MACs + HUVECs in the insert. 



































Figure 11. Quantification results from the third experiment of MACs and HUVECs co-
cultured in Transwell®. Increased networks per mm2 and increased network lengths per 
mm/mm2 at all time points are highest when HUVECs were co-cultured with only MACs 
in the insert. No significant difference is seen between the groups when network branch 










3.1 Culture conditions influence cell growth and formation of tube-like structures  
In this project, culture conditions for co-cultures of HUVECs and MSCs were optimised 
using EGM or EGM 2 media and cells were grown on either non-coated wells or on wells 
coated with fibronectin. Cell adhesion, proliferation and formation of tube-like structures 
were used as parameters to assess cell viability and survival in the different conditions 
tested. 
 
Fibronectin is an ubiquitous high molecular weight glycoprotein commonly found in 
ECM. It plays a major role in attaching cells to the ECM and mobilising them during 
embryonic development and wound healing and is pertinent for the development of 
vascular structures. Researchers have shown that coating of culture plates with connective 
proteins increases the potential of MSCs to adhere, expand and spread in in vitro cultures 
(Yeo & Weiss, 2019). Relou et al., have also shown that HUVECs show better EC 
proliferation when cultured on plates coated with fibronectin, collagen, gelatin and 
hyaluronan compared to cultures on non-coated surfaces. Our results are in alignment 
with this theory and a clear trend of better cell survival and tube-like structure formation 
was seen when MSCs and HUVECs were co-cultured on fibronectin coated plates.  
 
Endothelial growth media (EGM) and endothelial growth media 2 (EGM 2) are both low 
serum culture media with endothelial growth supplement factors. The major difference 
between the two is that EGM 2 contains VEGF and insulin-like growth factor while EGM 
lacks these but contains endothelial cell growth supplement extracted from bovine 
hypothalamus. Researchers have shown that VEGF secreted by MSCs increases 
angiogenic sprouting of HUVECs (Beckermann et al., 2008). The results from our 
optimisation experiments however show that the cells grow better and HUVECs have 
better tube formation capacity, when cultured in EGM alone with fibronectin coating. 
This observation is a little perplexing, since it is a well known fact that VEGF promotes 
angiogenesis, while, in our experiments, when the cells were co-cultured in EGM 2 
containing VEGF, no significant tubes were formed nor was the cell proliferation high. 
These results were extrapolated for the other experiments in this project and good cellular 
viability was seen when primary cells of our interest were co-cultured with HUVECs in 
EGM on fibronectin coated wells. However, no clear evidence behind why the cells prefer 
EGM to EGM 2 was found.  
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Furthermore, no statistically significant differences between the groups was seen when 
tube formation and network parameters were quantified, despite the fact that we observed 
clear morphological evidence that cells cultured in EGM with fibronectin coated plates 
survived better. This indicates that although these culture conditions promote cell 
viability, they may perhaps not have that much effect on the proangiogenic capacity of 
ECs and on the capacity of MSCs to support angiogenesis. Going forward, culture 
conditions could be slightly modified by the addition of exogenous cytokines or growth 
factors to see if these affect or promote better tubulogenesis when MSCs and HUVECs 
are co-cultured.  
 
3.2 MSCs and HUVECs cultured in Transwell® setup give rise to tube like structures 
During this project, we aimed to see if MSCs and HUVECs interact with each other in a 
paracrine manner to induce formation of tubular structures as seen in de novo  
vascularisation. In order to assess this, we cultured MSCs in a Transwell® cell culture 
insert. These inserts are porous membranes that facilitate cell-cell interaction and 
exchange of soluble bioactive molecules between the cells.  
 
Researchers have shown that MSCs can act as a source of VEGF and the presence of 
VEGF, a positive regulator of angiogenesis, has been observed in cultures of human 
MSCs (Kagiwada et al., 2008). Others have shown that when MSCs were co-cultured 
with HUVECs without the presence of any ECM proteins, expression of the VEGF-A 
gene was greatly enhanced compared to monoculture groups (Oki et al., 2018). They 
further also showed that when HUVECs and MSCs were co-cultured without any ECM 
proteins, lumen-like structures were observed after just 72 hours of culturing. These 
studies indicate that MSCs play a profound role in enhancing the angiogenic capacity of 
HUVECs to form tubular structures. Based on this existing evidence, we wanted to see if 
MSCs can still influence HUVECs to form these lumen like structures, when they were 
not grown in direct contact with each other.  
 
In our experiments, we plated HUVECs with the MSCs in a Transwell® setup. Here, we 
tried to see if MSCs can still influence HUVECs to form tubular structures by releasing 
any soluble, paracrine pro-angiogenic factors. Results show that MSCs are capable of 
influencing HUVECs to form tube like structures, even if they are cultured in a 
Transwell®  setup where they are not in direct contact with the endothelial cells.  
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Unfortunately, no statistically significant differences were found between the groups 
when the number of networks, network length and network branch point parameters were 
quantified. Further, our HUVECs were also plated onto culture wells coated with 
fibronectin. When MSCs were co-cultured with HUVECs in the cell culture insert and 
HUVECs at the bottom of the well, slight increases in network length and network branch 
points were noted. The reason behind this is not fully known, but we can at least conclude 
that MSCs do secrete certain paracrine factors that facilitate this tube formation. Whether 
this certain factor is VEGF or something else was not elucidated in this project and further 
assays like RT-PCR and ELISA need to be conducted to investigate the molecular 
mechanisms behind this phenomenon.  
 
3.3 Functionality of MACs using in vitro Transwell® co-culture models  
The central aim of this project was to test the functionality of MACs when co-cultured 
with HUVECs in a Transwell® setup. To achieve this, PB-MNCs were first co-cultured 
with MSCs and later our cells of interest, i.e., MACs expressing the CD14 and CD31 
markers were isolated by means of magnetic-activated cell sorting. These MACs were 
then placed in cell culture inserts and cultured with HUVECs.  Our lab has previously 
observed that when MNCs and MSCs are co-cultured, EC-like, spindle shaped cells 
positive for CD31, CD14 and CD45 surface markers are formed. These monocytic cells 
were assumed to be the MAC population and both 2D and 3D co-cultures with HUVECs 
were done to check if they can support angiogenesis in vitro. The results of these 
experiments showed that MACs are indeed proangiogenic in nature and induce looping 
and branching structures in HUVECs when co-cultured (Uusitalo-Kylmälä et al., 2021). 
Based on these previous observations, we hypothesized that MACs with HUVECs in a 
Transwell® setup interact to form tube-like angiogenic structures and that this tube 
formation is either affected by the cell-cell contact and secreted paracrine growth factors 
or both.  
 
Results from the experiments show quite conflicting data. In the first set of experiments, 
the most number of networks per mm2 and network length per mm/mm2 were seen when 
HUVECs were co-cultured with MACs and HUVECs in a Transwell® insert. Data from 
the first set of experiments also showed that network formation peaked around day 4 for 
all groups. This raises the question whether secretion of paracrine factors peaks during 




During the second attempt, extremely inconsistent results were seen. The highest number 
of networks per mm2 were seen when HUVECs were co-cultured with MACs and 
HUVECs in a Transwell® insert. However, increased number of network branch points 
and network length was seen in the control group where HUVECs and MACs were co-
cultured with no cell culture inserts. In the final attempt, maximal network formation per 
mm2 and network length per mm/mm2 were seen when HUVECs were co-cultured with 
only MACs in the insert. When network branch points were considered, no real difference 
between the control groups and experimental groups were observed in any of the three 
experiments.  
 
Furthermore, no statistical difference was found between any of the groups despite the 
fact that clear morphological evidence of looping and branching structures were seen 
when these cells were microscopically evaluated. In conclusion, our hypotheses that 
MACs interact with HUVECs in a Transwell®  setup to produce tubular structures as seen 
in de novo vascularisation was proved right to a certain extent. However, the exact 
mechanisms by which these cells interact still remains unknown. These results also do 
not help to determine if culturing these cells in a Transwell® setup boosts their 
proangiogenic capabalities compared to when they’re grown in a conventional direct co-
culture model. 
 
3.4 Limitations of this study 
This project has quite a few limitations and falls short on several fronts. Firstly, the cells 
used for the entirety of this study are primary cells. Primary cells by nature are quite 
heterogenous and function a little different from culture to culture. Variations are also 
due to methodological differences that occur during isolation of MACs from MSC-MNC 
co-cultures. Also personnel inexperience and technical variations can further amplify 
these differences. The number of MACs that were isolated also varied from experiment 
to experiment. For instance, during the second isolation procedure, quite low number of 
MACs were obtained despite following the exact protocol. This in turn gave very poor 
and confusing results, when these MACs were plated with HUVECs in Transwell® setup. 
This issue could probably be sorted if the procedures were conducted by a more 
experienced researcher. Next, cells were cultured for upto 14 days in the IncuCyte®. This 
is quite a long time period and although cells did not die, the number of viable cells 
decreased over time in all the groups. However, reducing the number of culture days is 
not helpful, as the formation of tubular structures only takes places around day 10.  
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Maybe adding exogenous growth factors could help in improving cell viability; however, 
this was not ideal or recommended here, since the main aim of this project was to see if 
MACs release any proangiogenic factors of their own to influence the formation of tubes. 
Nevertheless, it is wise to consider if better tube formation could have been observed if 
the cells remained viable for a prolonged period of time. The first time these cells were 
placed in the IncuCyte®, we noticed cells dying at quite an alarming rate. We later found 
out that this was because the IncuCyte® is a shared imaging instrument and increased 
number of people kept on opening and closing the apparatus, thus causing the media to 
evaporate and altering the required cell culture conditions. This issue was resolved by 
adding PBS to the empty wells and normal cell growth was observed in the future 
experiments.  
 
In this project, we placed the culture plates in the IncuCyte® for the entire 14 day period. 
Endothelial cells do not form any visible tubular structures for the first one week of 
culturing and thus Incucyte® could be utilized only during the last week of culture. 
Nevertheless, by this approach any potential changes happening prior to this timeframe, 
would be missed. Although numerical data does show that network formation and 
network length peaks around day 4, this was not visibly seen when the IncuCyte® acquired 
automated images of the plate. Placing the plate in the IncuCyte® for so long also 
deteriorates the cell health since constant opening and closing of the IncuCyte® door 
affects cells in a negative manner.  
 
Futhermore, primary cells are very sensitive cells and ensuring their survival is quite 
difficult in a monoculture let alone in a co-culture model. MACs isolation from the MSC-
MNC co-culture is also quite a time consuming process and these cells need to be freshly 
isolated before every experiment. These cells are non-proliferative and do not survive 
freezing. These properties make them not very easy to work with. Obtaining consistent 
in vitro results with experiments conducted using these cells is quite a challenge and 
requires careful planning and execution. Finally, in this study we did not investigate what 
proangiogenic factors were released by the MACs to induce tube formation in co-culture 
models, but it will be the topic of future studies. Pinpointing these factors will provide 
more substantial insights into the cellular crosstalk that takes place during the 





3.5 Future directions for studying angiogenesis using MACs and co-culture models  
Going forward, a few changes can be done when using this Transwell set up for co-culture 
models. Firstly, finding an alternative way to image the co-cultured cells instead of using 
the IncuCyte® real time imaging system could help in obtaining more consistent results. 
In case the, image acquistion and tube formation parameters are done using the 
IncuCyte®, the cells could be cultured in a normal incubator for the first week and then 
transferred to the IncuCyte®. Second, in this project, we never tested if MACs cultured 
alone are capable of forming tube-like structures on their own. Future studies should at 
least include this as a control group to assess the true tube forming capacity of these 
monocytic cells. Finally, media in which the cells were cultured was collected during this 
project at various time points. However, due to time constraints we were not able to run 
ELISA assays using this conditioned media. Kwon et al., (2014) have already been able 
to show that conditioned media obtained from human MSC cultures contain several 
growth factors such as VEGF, hepatocyte growth factor (HGF), monocyte chemotactic 
protein-1 (MCP-1), interleukin-6 (IL-6), and transforming growth factor-beta1 (TGF-β1), 
which augment the angiogenic potential of endothelial cells in vitro.  
 
In the future, conditioned media used to culture the cells should be tested to elucidate, 
which proangiogenic factors are secreted by the cells when they are cultured in a 
Transwell® setup with no direct cell-cell contact. Understanding which molecules play a 
key role in the angiogenesis process can help in pinpointing the key regulators of 
neovascularisation. Furthermore, once the cytokines and growth factors are known, cells 
could be modified by gene expression technologies and upregulation of the corresponding 
gene may lead to enhanced vascularisation or promote better tubule formation. 
 
 
4 MATERIALS AND METHODS 
 
4.1 Cell culture 
4.1.1 Human mesenchymal stem cells  
Human mesenchymal stem cells (MSCs) were harvested from the iliac bone marrow of a 
healthy 21-year-old female donor after an informed consent form under the protocol 
approved by the Ethics committee of the Helsinki University Central Hospital, Finland, 
was signed. Cells were then isolated, expanded, and cryopreserved in liquid nitrogen 
using previously optimized methods.  
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In this project, cells were thawed prior to use and cultured in α- minimal essential medium 
(α- MEM; Gibco, Grand Island, USA, Ref no. 41061-029) containing 10% foetal bovine 
serum (FBS; U.S. origin, Invitrogen, cat#16000-044) and 1% penicillin streptomycin (PS, 
Gibco) henceforth referred to as basal media. Cells at passages 6 to 8 were used for the 
experiments. 
 
4.1.2 Human umbilical vein endothelial cells  
Commercially available GFP-expressing human umbilical vein endothelial cells (GFP-
HUVECs) (IncuCyte® Cytolight Green HUVECs, Essen Bioscience, Sartorius, cat#4453) 
were expanded and cultured in Endothelial Growth Medium 2 (EGM 2, PromoCell, C-
22011) with the Supplemental Mix (PromoCell GmbH, Heidelberg, Germany, cat# 
39216) and 1% penicillin streptomycin (PS, Gibco). Cells were cryopreserved in liquid 
nitrogen and thawed prior to use in experiments. Cells at passages 7-8 were used for the 
experiments. 
 
4.1.3 Peripheral blood-derived mononuclear cells 
Peripheral blood sample (average volume 30 mL) was collected from one healthy 25-
year-old male donor. The local Ethical Committee of University of Turku approved the 
protocol, and the donor signed an informed consent. Blood was always drawn on the day 
of the experiment and mononuclear cells were isolated from the freshly drawn blood 
samples by Ficoll density gradient centrifugation method and cultured with MSCs as 
described below (see 4.3). 
 
4.2 Optimization of culture conditions 
Culture conditions for optimal tube formation when MSCs and HUVECs were grown 
together was checked using four different parameters i.e., Endothelial Growth Media 
(EGM, PromoCell, C-22010) with Supplemental Mix (PromoCell GmbH, Heidelberg, 
Germany, cat# 39215) and 1% PS, EGM 2, fibronectin coating and no fibronectin coating. 
The cells were plated in a 96 well plate (96-Well CytoOne® Plate, TC-Treated, 
cat#CC7682-7596) and wells of the fibronectin groups were coated with 1 ng/mL 
fibronectin prior to plating cells.  Experimental groups were as follows: MSCs and 
HUVECs in EGM media with fibronectin coating, MSCs and HUVECs in EGM media 
without fibronectin coating, MSCs and HUVECs in EGM 2 media with fibronectin 
coating, and MSCs and HUVECs in EGM 2 media without fibronectin coating. Control 
groups were as follows: MSCs alone in EGM without fibronectin, MSCs alone in EGM 
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with fibronectin, HUVECs alone in EGM without fibronectin and HUVECs alone in 
EGM with fibronectin. Similar control groups with EGM 2 were included as well. Cells 
were seeded at a density of 500 cells/well for MSCs and 1000 cells/well in the case of 
HUVECs. Cells were observed using real time cell imaging software IncuCyte® S3. Half 
of the media was changed every alternate day.  
 
4.3 MSC-MNC co-culture for MACs isolation 
The co-culture set up was prepared in such a way that MSCs were thawed and cultured 
first in one or two T75 flasks in basal medium (1000 cells/cm2). Half of the medium was 
changed every 3-4 days. Cells were allowed to reach confluency and then harvested using 
trypsin/EDTA (Gibco) before re-plating into three T75 flasks (1000 cells/cm2). After one 
week of expansion, cells were harvested again, re-plated onto three T75 flasks (2500 
cells/cm2) for experiments, and allowed to grow for 3 days. Mononuclear cells (MNCs) 
were isolated from the peripheral blood sample using Ficoll density gradient 
centrifugation method (Ficoll-Paque PLUS, GE Healthcare Bio-Sciences AB, Sweden). 
The MNCs were added to the flasks containing MSCs at a cell density of 50000 cells/cm2. 
Cells were cultured in basal media for one week and half of the medium was changed 
every 3-4 days.  
 
4.4 Magnetic-activated cell sorting for isolation of MACs from PB source 
Endothelial progenitor cells of our interest i.e., CD14+CD31+ cells, hereafter referred to 
as Myeloid Angiogenic Cells (MACs) were isolated from the MSC-MNC co-culture by 
means of magnetic activated cell sorting (MACS®). Cell sorting was performed with 
magnetic nanoparticles coated with antibodies against CD14+ and CD31+ according to 
the manufacturer’s instructions (Miltenyi Biotec). Cells in the co-culture were trypsinised 
and counted. After counting, the cell suspension was subjected to centrifugation at 300 g 
for 10 minutes, supernatant was discarded, and the pellet was dissolved in 80 µL of cold 
buffer (1x PBS + 1% FBS), henceforth known as MACS buffer. 20 µL of CD14 
microbeads (Miltenyi Biotec, 130-050-201) were added per 107 cells. The mixture was 
incubated at 4°C in a cold room rotator for 15 mins. The cell suspension was then 
subjected to a strong magnetic field (Miltenyi Biotec) with a LS column (Miltenyi Biotec, 
130-042-401). The cells expressing the surface markers CD14 and CD31 remain in the 
column while the remaining non-specific cells were collected separately. The LS column 
is then removed from the magnetic field, and cells positive for CD14 were eluted by 
washing the column with 5 mL of cold MACS buffer. Cells were centrifuged for 5 
33 
 
minutes at 300 g. The supernatant was discarded, pellet was dissolved in 1 mL EGM and 
cells were counted. After counting, cells were again centrifuged for 3 minutes at 300 g. 
Supernatant was aspirated and cells were resuspended in 60 µL of EGM. 20 µL of FcR 
blocking reagent (Miltenyi Biotec, 130-059-901) was added to this suspension followed 
by 20 µL of CD31 microbeads (Miltenyi Biotec, 130-046-702) per 107 cells. The mixture 
was incubated at 4°C in a cold room rotator for 15 mins. 1 mL of EGM was added to the 
cell suspension and cells were centrifuged at 300 g for 3 minutes. Cell pellet was 
resuspended in EGM medium and subjected to magnetic field as mentioned above. 
Unlabelled cells were collected as flow through and CD14+CD31+ cells were eluted with 
5 mL of EGM medium as aforementioned. Cell suspension was then centrifuged again at 
300 g for 5 minutes. Supernatant was discarded and pellet was resuspended in 1 ml EGM. 
Cells were then counted. The cell sorting success by this protocol was previously checked 
by our lab using flow cytometry analyses.  
 
4.5 Transwell® cell culture set up  
4.5.1 Transwell® co-culture with HUVECs and MSCs 
Cells were cultured in a 24-well plate (Corning cat# 356008) coated with fibronectin (1 
μg/ml) with 0.4 µm inserts (Falcon® Permeable Support Transparent PET Membrane, 
cat# 353095) to see if HUVECs in the presence of MSCs give rise to tube-like structures. 
HUVECs were plated a day before to allow cells to attach to the plate and the following 
day MSCs were harvested as described above and added to the inserts and wells. 
HUVECs were seeded at a density of 6000 cells/well and 1000 cells/insert. MSCs were 
seeded at a density of 3000 cells/well and 500 cells/insert. Control groups included 
HUVECs alone and HUVECs with MSCs without inserts. Experimental groups included 
HUVECs in the well with MSCs alone in insert and HUVECs in the well with MSCs as 
well as HUVECs in the insert (Figure 12). Cells were cultured in EGM for at least 14 
days. Three biological replicates were performed, and each experimental sample group 
consisted of three parallel technical replicates. 
 
Figure 12. Diagrammatic representation of experimental groups in the Transwell® co-
culture model with HUVECs and MSCs. 
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4.5.2 Transwell® co-culture with HUVECs and MACs 
Cells were cultured in a 24-well plate (Corning cat# 356008) coated with fibronectin (1 
μg/ml) with 0.4 µm inserts (Falcon® Permeable Support Transparent PET Membrane, 
cat# 353095). HUVECs were plated a day before to allow cells to adhere to the plate and 
the following day MACs were isolated from MSC-MNC co-culture as described above 
and added to the wells and inserts. Cells were seeded at a density of 6000 HUVECs/well 
and 12,000 MACs/well. Cells in the insert were plated at a density of 1000 cells/insert for 
HUVECs and 2000 cells/insert for MACs. Control groups included HUVECs alone and 
HUVECs with MACs without inserts. Experimental groups included HUVECs in the well 
with MACs alone in insert and HUVECs in the well with MACs as well as HUVECs in 
the insert. Cells were cultured in EGM for at least 14 days. Half of the media used to 
culture the cells in was changed every alternate day. Three biological replicates were 




4.6 Real time cell imaging (IncuCyte® S3 live-cell analysis) 
HUVECs and MACs were co-cultured in a 24-well plate setup with Transwell® inserts as 
described above. Cell proliferation, morphological and structural changes were observed 
using the real-time cell imaging system (IncuCyte® S3, Sartorius).  
Cells were imaged and images were stored automatically by the system at regular 2- or 
4-hour intervals. Images were taken with the 10x objective. IncuCyte® Angiogenesis 
Analysis Software Module (Cat. No. 9600-0011) was used to analyze the number and 
length of networks, as well as the number of network branch points.  
 
 
4.7 Microscopy imaging 
Cells were fixed with paraformaldehyde after 14 days of culturing and cell morphology 
and tube-like structures were imaged using both a standard light microscope and 
multichannel fluorescence microscope (EVOS M5000). Images were acquired using a 







4.8 Statistical methods 
Statistical analyses and quantification graphs were made using Graph Pad Prism 9. 
Statistical significances between the experimental groups were assessed using the One-
Way-ANOVA followed by Bonferroni multiple comparison test. All experiments were 
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6 ABBREVIATIONS  
 
2D – two-dimensional 
3D – three-dimensional  
CAC – Circulating angiogenic cell 
CAD – Coronary Artery Disease 
CD14 – Cell differentiation marker 14  
CD31 - Cell differentiation marker 31  
CD45 - Cell differentiation marker 45 
CD146 – Cell differentiation marker 146  
EC - Endothelial cell  
ECFC - Endothelial colony forming cell  
ECM – Extracellular matrix 
EGM – Endothelial Growth Media 
EGM 2 – Endothelial Growth Media 2 
EPC - Endothelial progenitor cell  
HUVEC - Human umbilical vein endothelial cell  
MAC - Myeloid angiogenic cell  
MMP – Matrix metalloprotease 
MNC - Mononuclear cell  
MSC - Mesenchymal stromal cell  
PB-MNC – Peripheral blood-derived mononuclear cell 
VEGF - Vascular endothelial growth factor 
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